Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Reports Encouraging Preliminary Data

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced today that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.

The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Quantum BioPharma believes this approach could enhance the development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026.

Full press release details are available here.

Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis.

The company also developed UNBUZZD(TM), an over-the-counter product, and spun it out to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.). Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.